Author:
Heil G.,Mitrou P. S.,Hoelzer D.,Freund M.,Link H.,Ehninger G.,Steinke B.,Öhl S.,Wandt H.,Fackler-Schwalbe E.,Schlimok G.,Lösch A.,Queißer W.,Löffler B.,Gaus W.,Högel J.,Heimpel H.,Kurrle E.
Publisher
Springer Berlin Heidelberg
Reference25 articles.
1. Stone RM, Mayer RJ. Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. Hamatol Oncol Clin North Am 1993; 7: 47–64.
2. Büchner T. Acute leukemia. Curr Opin Hematol 1993; 1: 172–182.
3. Mayer RJ. Current chemotherapy treatment approaches in the management of previously untreated adults with de novo acute myelogenous leukemia. Semin Hematol 1987; 14: 384–396.
4. Capizzi RL, Yang J, Rathmell JP, White JC, Cheng E, Cheng Y, Kute T. Dose-related pharmacologic effects of high-dose ara-C and its self-potentiation. Seminars in Oncology 1985; 12, suppl. 3: 65–75.
5. Kantarjian HM, Estey EH, Plunkett W, Keating MJ, Walters RS, Iacoboni S, McCredie KB, Freireich EJ. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am j Med 1986; 81: 387–394.